Solx, Inc.

Solx, Inc.


Solx, Inc. is developing the Gold Shunt for the reduction of intraocular pressure in glaucoma, a disease of the eye which can result in damage to the optic nerve and blindness. Use of surgical devices for glaucoma is expected to be a growing segment of ophthalmology due to strong clinical results, attractive health economic benefits and persistent unmet clinical need.

The Solx Gold Shunt is an implantable, patent protected device that allows fluid to drain from the anterior chamber of the eye to the suprachoroidal space without the need for a bleb, thereby avoiding bleb-related complications that have been a significant gating factor to the extent and performance of traditional filtering surgeries. Over 2,000 Gold Shunts have been implanted in human eyes showing compelling and durable efficacy with a favourable safety profile.

Contact Name
Mr. Kevin J McMahon

Company Position
President & Chief Executive Officer

Contact Email

Contact Address
230 Second Avenue, Suite 120
MA 02451